Previous 10 | Next 10 |
Ultragenyx Pharmaceutical ( RARE ) delivered an exceptional Q4 '18 and fiscal year 2018 results, beating the top-line analysts' estimates. Following the earnings results, the stock price surged over 6% on February 19, 2019. The management is confident about the strong business performance in 2...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
24-week results from three patients in the lowest dose cohort in a Phase 1/2 clinical trial evaluating Ultragenyx's (NASDAQ: RARE ) gene therapy DTX401 in glycogen storage disease type Ia (GSDIa) showed a positive effect. More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks n...
DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients Data from Higher-dose Cohort 2 Expected Mid-2019 NOVATO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with their 2018 Q4 earnings Read more ...
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2018 Earnings Conference Call February 19, 2019 5:00 PM ET Company Participants Danielle Keatley – Senior Director-Investor Relations and Corporate Communications Emil Kakkis – Chief Executive Officer and President Vlad Hogen...
Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself i...
Ultragenyx (NASDAQ: RARE ) Q4 result s ($M): Revenues: 16.3 (+579.2%); Crysvita-related revenue: 11.6. More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Ultragenyx Pharmaceutical (NASDAQ: RARE ): Q4 GAAP EPS of -$1.73 beats by $0.05 . More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NOVATO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results and corporate update for the quart...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...